abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
ActR2
Back
Total number of drugs
31
Phase II and later clinical stages
16.1%
Involving companies
55
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
LAE-123LAE-123AntibodyNervous System Diseases Other DiseasesACVR2A inhibitors ACVR2B inhibitorsLaekna Therapeutics (Shanghai) Co., Ltd.Laekna Therapeutics (Shanghai) Co., Ltd.DiscoveryDiscovery--------LAE-123--
detail  >
SPCD-4-79SPCD-4-79Small molecule drugEndocrinology and Metabolic DiseaseACVR2A inhibitors ACVR2B inhibitorsEast China Normal University Fudan UniversitySupercede Therapeutics, Inc.Preclinical---------SPCD-4-79--
detail  >
GenSci156GenSci156Bispecific antibodyEndocrinology and Metabolic DiseaseACVR2A inhibitors ACVR2B inhibitors GIPR modulatorsChangchun Genescience Pharmaceuticals Co., Ltd.Changchun Genescience Pharmaceuticals Co., Ltd.PreclinicalPreclinical--------GenSci156--
detail  >
ActRII A/B monoclonal antibody (CSPC Pharmaceutical)ActRII A/B monoclonal antibody (CSPC Pharmaceutical)Monoclonal antibodyEndocrinology and Metabolic DiseaseACTRII inhibitorsCSPC Pharmaceutical Group Ltd.CSPC Pharmaceutical Group Ltd.PreclinicalPreclinical--------ActRII A/B monoclonal antibody (CSPC Pharmaceutical)--
detail  >
IMC-004 (ImmuneOnco)IMC-004 (ImmuneOnco)Bispecific antibodyNervous System Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Other DiseasesACVR2A inhibitorsImmuneOnco Biopharmaceuticals (Shanghai), Inc.ImmuneOnco Biopharmaceuticals (Shanghai), Inc.PreclinicalPreclinical--------IMC-004 (ImmuneOnco)--
detail  >
ActRIIB inhibitor (Fudan University)ActRIIB inhibitor (Fudan University)Small molecule drugOther DiseasesACVR2B inhibitorsFudan UniversityFudan UniversityPreclinicalPreclinical--------ActRIIB inhibitor (Fudan University)--
detail  >
rAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne)rAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne)AAV based gene therapyOther DiseasesACVR2B inhibitors Gene transferenceBaker Heart & Diabetes InstituteBaker Heart & Diabetes Institute Monash University University of MelbournePreclinical---------rAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne)--
detail  >
Pulmonary Arterial Hypertension Treatment (AliveGen)Pulmonary Arterial Hypertension Treatment (AliveGen)Fusion proteinRespiratory Diseases Other DiseasesACVR2B agonists-AliveGen USA, Inc.Preclinical----Orphan Drug(United States)----Pulmonary Arterial Hypertension Treatment (AliveGen)--
detail  >
ACE-2494ACE-2494Fusion protein-ACVR2A inhibitors ACVR2B modulators MSTN inhibitorsAcceleron Pharma, Inc.-Pending (in Phase 1)---------ACE-2494--
detail  >
ATA M43ATA M43Bispecific antibodyNervous System Diseases Other DiseasesACVR2A inhibitors ACVR2B inhibitorsAmgen, Inc.-Pending (in Preclinical)---------ATA M43--
detail  >
Total 31 data
1
2
3
4